Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2024/2025
The following technology appraisals have been endorsed during 2024/25. Information on technology appraisals endorsed in previous years can be found on the homepage.
August 2024
TA990 - Tenecteplase for treating acute ischaemic stroke
TA986 - Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
July 2024
Note this guidance partially updates NICE Technology Appraisal TA688, endorsed by the DoH in April 2021
June 2024
TA981 - Voxelotor for treating haemolytic anaemia caused by sickle cell disease
TA979 - Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
Note this guidance updates and replaces NICE Technology Appraisal TA554, endorsed by the DoH in March 2019.
TA974 - Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma
TA973 - Atogepant for preventing migraine
TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
May 2024
Note this guidance partially updates and replaces NICE Technology Appraisal TA540, endorsed by the DoH in March 2019.
TA964 - Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
April 2024
Note this guidance updates and replaces NICE Technology Appraisal TA598, endorsed by the DoH in September 2019.
TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms
TA955 - Dupilumab for treating moderate to severe prurigo nodularis
TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema
Note this guidance updates and replaces NICE Technology Appraisals TA613, endorsed by the DoH in December 2019 and TA301, endorsed by the DoH in December 2013.